PMID- 23430574
OWN - NLM
STAT- MEDLINE
DCOM- 20131017
LR  - 20220317
IS  - 1439-3646 (Electronic)
IS  - 0947-7349 (Linking)
VI  - 121
IP  - 4
DP  - 2013 Apr
TI  - Metabolic effects of L-carnitine on type 2 diabetes mellitus: systematic review 
      and meta-analysis.
PG  - 234-8
LID - 10.1055/s-0033-1333688 [doi]
AB  - INTRODUCTION: Carnitine is an endogenous metabolite and exogenous nutrient with a 
      pivotal role in lipid metabolism. Plasma levels of carnitine are reduced in type 
      2 Diabetes Mellitus (T2DM). The aim was to evaluate the metabolic effects of the 
      administration of L-carnitine in T2DM. METHOD: A systematic review was performed. 
      Relevant randomized, controlled-trials trials were searched in Pubmed, Trip 
      Database and Cochrane Library, and selected when they had enough methodological 
      quality assessed with the Jadad scale. Article search strategy included 
      "Carnitine" OR "L-carnitine" AND "Diabetes -Mellitus" OR "Diabetes mellitus, type 
      2" OR "Noninsulindependent-diabetes mellitus". Meta-analysis was performed, and 
      the difference of means calculated with a 95% confidence interval. Heterogeneity 
      was evaluated with the Q statistic. RESULTS: The systematic review included 4 
      trials with 284 patients. Oral L-carnitine lowered fasting plasma glucose [-14.3 
      mg/dl (CI95% - 23.2 to -5.4); p=0,002], total cholesterol [-7.8 mg/dL (95%CI 
      -15.5 to -0.1); p=0.09], low density lipoprotein [-8.8 mg/dl (CI95% -12.2 to 
      -8.5), p<0.0001], apolipoprotein-B100 [-7.6 mg/dl (CI95% -13.6 to -1.6); p=0.013] 
      and apolipoprotein-A1 [-6.0 mg/dl (CI95% -10.5 a -1.5); p=0.523]. There was no 
      significant heterogeneity. The changes in triglycerides, lipoprotein (a) or 
      HbA(1c) were not significant. CONCLUSION: The administration of L-carnitine in 
      type 2 diabetes mellitus is associated with an improvement in glycaemia and 
      plasma lipids.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
FAU - Vidal-Casariego, A
AU  - Vidal-Casariego A
AD  - Seccion de Endocrinologia y Nutricion, Complejo Asistencial Universitario de 
      Leon, Leon, Spain. avcyo@hotmail.com
FAU - Burgos-Pelaez, R
AU  - Burgos-Pelaez R
FAU - Martinez-Faedo, C
AU  - Martinez-Faedo C
FAU - Calvo-Gracia, F
AU  - Calvo-Gracia F
FAU - Valero-Zanuy, M A
AU  - Valero-Zanuy MA
FAU - Luengo-Perez, L M
AU  - Luengo-Perez LM
FAU - Cuerda-Compes, C
AU  - Cuerda-Compes C
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20130221
PL  - Germany
TA  - Exp Clin Endocrinol Diabetes
JT  - Experimental and clinical endocrinology & diabetes : official journal, German 
      Society of Endocrinology [and] German Diabetes Association
JID - 9505926
RN  - 0 (Apolipoprotein A-I)
RN  - 0 (Apolipoprotein B-100)
RN  - 0 (Blood Glucose)
RN  - 0 (Insulin)
RN  - 0 (Lipids)
RN  - 0 (Lipoproteins, LDL)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - S7UI8SM58A (Carnitine)
SB  - IM
MH  - Apolipoprotein A-I/blood
MH  - Apolipoprotein B-100/blood
MH  - Blood Glucose/analysis
MH  - Carnitine/administration & dosage/*therapeutic use
MH  - Cholesterol/blood
MH  - Diabetes Mellitus, Type 2/*blood/*drug therapy
MH  - Fasting
MH  - Humans
MH  - Insulin/blood
MH  - Lipids/blood
MH  - Lipoproteins, LDL/blood
MH  - MEDLINE
MH  - Postprandial Period
MH  - Randomized Controlled Trials as Topic
EDAT- 2013/02/23 06:00
MHDA- 2013/10/18 06:00
CRDT- 2013/02/23 06:00
PHST- 2013/02/23 06:00 [entrez]
PHST- 2013/02/23 06:00 [pubmed]
PHST- 2013/10/18 06:00 [medline]
AID - 10.1055/s-0033-1333688 [doi]
PST - ppublish
SO  - Exp Clin Endocrinol Diabetes. 2013 Apr;121(4):234-8. doi: 10.1055/s-0033-1333688. 
      Epub 2013 Feb 21.